Identification of MK-1925: A selective, orally active and brain-penetrable opioid receptor-like 1 (ORL1) antagonist

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 16, 2009, Pages 4729-4732

  Kobayashi, Kensuke ^a   Tsujita, Tomohiro ^a   Ito, Hirokatsu ^a   Ozaki, Satoshi ^a   Tani, Takeshi ^a   Ishii, Yasuyuki ^a   Okuda, Shoki ^a   Tadano, Kiyoshi ^a   Fukuroda, Takahiro ^a   Ohta, Hisashi ^a   Okamoto, Osamu ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Arylpyrazole; Nociceptin orphanin FQ; ORL1 antagonist

Indexed keywords

3 [5 (3,5 DIFLUOROPHENYL) 3 [[(3 FLUOROCYCLOPENTYL)AMINO]METHYL] 4 METHYL 1H PYRAZOL 1 YL]PROPANENITRILE; MK 1925; OPIATE ANTAGONIST; OPIOID RECEPTOR LIKE 1 ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; BRAIN; HUMANS; MICE; NITRILES; PYRAZOLES; RATS; RECEPTORS, OPIOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 67651121866     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.06.051     Document Type: Article

References (29)

1. Mollereau C., Parmentier M., Mailleux P., Butour J.L., Moisand C., Chalon P., Caput D., Vassart G., and Meunier J.C. FEBS Lett. 341 (1994) 33
2. Fukuda K., Kato S., Mori K., Nishi M., Takeshima H., Iwabe N., Miyata T., Houtani T., and Sugimoto T. FEBS Lett. 343 (1994) 42
3. Chen Y., Fan Y., Liu J., Mestek A., Tian M.T., Kozak C.A., and Yu L. FEBS Lett. 347 (1994) 279
4. Pan Y.X., Cheng J., Xu J., Rossi G., Jacobson E., Ryanmoro J., Brooks A.I., Dean G.E., Standifer K.M., and Pasternak G.W. Mol. Pharmacol. 47 (1995) 1180
5. Reinscheid R.K., Nothacker H.P., Bourson A., Ardati A., Henningsen R.A., Bunzow J.R., Grandy D.K., Langen H., Monsma F.J., and Civelli O. Science 270 (1995) 792
6. Meunier J.C., Mollereau C., Toll L., Suaudeau C., Moisand C., Alvinerie P., Butour J.L., Guillemot J.C., Ferrara P., Monsarrat B., Mazarguil H., Vassart G., Parmentier M., and Costentin J. Nature 377 (1995) 532
7. Mogil J.S., Grisel J.E., Reinscheid R.K., Civelli O., Belknap J.K., and Grandy D.K. Neuroscience 75 (1996) 333
8. Yu T.P., Fein J., Phan T., Evans C.J., and Xie C.W. Hippocampus 7 (1997) 88
9. Sandin J., Georgieva J., Schött P.A., Ögren S.O., and Terenius L. Eur. J. Neurosci. 9 (1997) 194
10. Manabe T., Noda Y., Mamiya T., Katagiri H., Houtani T., Nishi M., Noda T., Takahashi T., Sugimoto T., Nabeshima T., and Takeshima H. Nature 394 (1998) 577
11. Pomonis J.D., Billington C.J., and Levine A.S. Neuroreport 8 (1996) 369
12. Jenck F., Moreau J.L., Martin J.R., Kilpatrick G.J., Reinscheid R.K., Monsma F.J., Nothacker H.P., and Civelli O. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 14854
13. Gumusel B., Hao Q.Z., Hyman A., Chang J.K., Kapusta D.R., and Lippton H. Life Sci. 60 (1997) L141
14. Champion H.C., and Kadowitz P.J. Life Sci. 60 (1997) L241
15. Champion H.C., Wang R., Hellstrom W.J.G., and Kadowitz P.J. Am. J. Physiol. 36 (1997) E214
16. Chiou L.C., Liao Y.Y., Fan P.C., Kuo P.H., Wang C.H., Riemer C., and Prinssen E.P. Curr. Drug Targets 8 (2007) 117
17. Bignan G.C., Connolly P.J., and Middleton S.A. Expert Opin. Ther. Patents 15 (2005) 357
18. Zaveri N. Life Sci. 73 (2003) 663
19. Ronzoni S., Peretto L., and Giardina G.A.M. Expert Opin. Ther. Patents 11 (2001) 525
20. Kobayashi K., Uchiyama M., Ito H., Takahashi H., Yoshizumi T., Sakoh H., Nagatomi Y., Asai M., Miyazoe H., Tsujita T., Hirayama M., Ozaki S., Tani T., Ishii Y., Ohta H., and Okamoto O. Bioorg. Med. Chem. Lett. 19 (2009) 3627
21. Percent remaining after 30 min of incubation in cryopreserved human hepatocytes.
22. Kosugi M., Sumiya T., Ogata T., Sano H., and Migita T. Chem. Lett. (1984) 1225
23. 35S]GTPγS binding method.
24. J-113,397(Kawamoto, H.; Ozaki, S.; Itoh, Y.; Miyaji, M.; Arai, S.; Nakashima, H.; Kato, T.; Ohta, H.; Iwasawa, Y. J. Med. Chem. 1999, 42, 5061) was used as an internal control across all assay plates for data validation.
25. +.
26. Lynch J.J., Wallace A.A., Stupienski R.F., Baskin E.P., Beare C.M., Appleby S.D., Salata J.J., Jurkiewicz N.K., Sanguinetti M.C., Stein R.B., Gehret J.R., Kothstein T., Claremon D.A., Elliott J.M., Butcher J.W., Remy D.C., and Baldwin J.J. J. Pharmacol. Exp. Ther. 269 (1994) 541
27. Butcher, J. W. WO 2002005860, 2002; Chem. Abst. 2002, 136, 112612.
28. Hochman J.H., Yamazaki M., Ohe T., and Lin J.H. Curr. Drug Metab. 3 (2002) 257
29. A non-peptidyl synthetic agonist (WO03/10168; 0.3 mg/kg) was subcutaneously administered.